Anti-Snoring Treatment Market Report to 2031: Visiongain

Visiongain has published a new report on Anti Snoring Treatment Market Report till 2031. The market is segmented by devices, by surgery and by end-users. By Devices, the market is categorized as (Mandibular Advancement Devices, Nasal Devices, Continuous Positive Airway Devices, Others), by Surgery (Radio Frequency Palatoplasty, Uvulopalatopharyngoplasty (UPPP), Tonsillectomy, Laser Assisted Uvulopalatoplasty, Others) per end user (hospitals, retail pharmacies, others). Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa). The report includes detailed profiles of the major anti-snoring treatment companies. MORE COVID-19 Recovery Scenarios.

Download exclusive sample report @

The study covers detailed and insightful chapters on Market Overview, Market Segments, New Developments, Competitive Landscape, Strategic Recommendations, Key Company Analysis, Market Opportunities, Pricing Analysis , gap analysis, Porter’s 5 forces model, company profiling, geographic analysis and analytical insight. of the market. Advancement in anti-snoring devices and rising prevalence of sleep disorders are some of the factors driving the growth of the global anti-snoring treatment market.

Impact of COVID-19 on the Global Anti-Snoring Treatment Market

The COVID-19 pandemic has hugely affected the global anti-snoring market due to a series of lockdown and social distancing rules. In response to COVID-19, containment was initiated as a safety measure, implemented with isolation, social distancing and quarantine. This will likely reduce community transmission; however, this is a huge challenge for patients with sleep apnea. OSA patients have a high risk of hospitalization due to the outcome of COVID-19.

Market factors

Development of anti-snoring devices.

Snoring occurs when the tongue and the tissues of the mouth and throat become too relaxed, the air passing through develops vibrations in the tissues and creates loud snoring, due to which most people lose sleep . Snoring can be very disruptive and may indicate obstructive sleep apnea (OSA) or a more serious medical condition. Advanced anti-snoring devices are designed such as mandibular advancement devices, tongue stabilization devices, among others.

Increased tobacco and alcohol consumption

Obstructive sleep apnea (OSA) is a disorder characterized by partial or complete collapse of the upper airways leading to apnea during sleep. According to the National Institute of Health, the prevalence of OSA in the United States has been estimated to be around 15% in men and 5% in women between the ages of 30 and 70. OSA is common in people who drink alcohol and smoke because alcohol consumption eventually increases the collapsibility of the upper airways and contributes to a higher body mass index. Alcohol consumption and smoking among people are high risk associated with snoring and contribute to the anti-snoring treatment market.

Market opportunities

Increase awareness of sleep apnea and its treatment

According to the American Sleep Apnea Association, nearly 22 million Americans suffer from sleep apnea. Untreated apnea has serious health consequences, however, in recent years, people’s awareness of sleep apnea has increased and availability of devices is one of the factors driving the global sleep apnea market. anti-snoring treatments.

Get a detailed table of contents @

Competitive landscape

Apnea Sciences Corporation, Medtronic Plc, ASF Medical GmbH (Tomed GmbH), Fisher & Paykel Healthcare Limited, Koninklijke Philips NV, Meditas Ltd., Whole You Inc., ResMed Corp., SomnoMed Limited, The Pure Sleep Company are some of the key players contributing to the growth of the global anti-snoring treatments market. Market players are adopting new strategies to stay competitive in the global market, such as new product development, joint ventures, mergers and acquisitions, and geographic expansions.

For example, in March 2019, Apnea Sciences Corporation launched SnoreRx at Walgreens Apnea Sciences. The US FDA has cleared SnoreRx as an over-the-counter treatment oral device, which will be available at CVS pharmacies without a prescription.

In April 2019, ResMed launched AirFit P30i, its second crown-connected CPAP mask for the treatment of sleep apnea, a new nasal pillow option. The AirFit30i makes movement easier and allows home medical equipment (HME) providers to fit patients easier and faster.

Find quantitative and qualitative analyzes with independent predictions. Receive insights that only our report contains, staying informed with this valuable business intelligence.

To access the data contained in this document please email contact

Information found nowhere else
With our new report title, you’re less likely to fall behind in your knowledge or miss opportunities. See how our work could benefit your research, analysis and decisions. The Visiongain study is aimed at anyone who needs business analysis for the Anti-Snoring Treatment market and leading companies. You will find data, trends and forecasts.

Find more Visiongain research reports at Therapeutic drugs sector click on the following links:

Do you have any custom requirements that we can help you with? Do you need specific information about a specific country, geographic region, market segment or company? contact us todaywe can discuss your needs and see how we can help:

About Visiongain

Visiongain is one of the fastest growing and most innovative independent market intelligence companies. The company publishes hundreds of market research reports which it adds to its extensive portfolio every year. These reports offer in-depth analysis of 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which can currently influence each other, these markets include automotive, aviation, chemical, cyber, defence, energy, food and beverage, materials, packaging, pharmaceuticals and utilities. Our customized and syndicated market research reports mean you can have tailored market intelligence tailored to your own business needs.


Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
Tel EU: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Follow us: LinkedIn | Twitter

SOURCE Visiongain Limited.